Nasdaq GlobeNewswire

Aegerion Pharmaceuticals Observes World Lipodystrophy Day

Del

CAMBRIDGE, Mass., 2016-03-31 09:00 CEST (GLOBE NEWSWIRE) --

Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat debilitating rare diseases, announced today its observance of World Lipodystrophy Day.

Chief Executive Officer Mary Szela said, "We support the Association of Families Affected by Lipodystrophies in Spain, Europe & Latin America (AELIP), Lipodystrophy United (LU), and others in the lipodystrophy community in their objective to increase awareness and diagnosis of this serious and often undiagnosed rare disease. Education is an important step towards making an impact for people affected by lipodystrophy.”

Lipodystrophy is a group of rare diseases characterized by the lack of fat tissue. In some patients, it is genetic, and in others it may be acquired. It can be characterized by a widespread lack of fat tissue under the skin (generalized lipodystrophy) or limited lack of fat tissue (partial lipodystrophy). This loss of fat tissue might cause a deficit in the hormone leptin leading to multiple medical complications such as severe metabolic complications.

“Lipodystrophies are rare diseases, meaning they can be difficult to diagnose correctly and therefore treat properly and efficiently,” said David Araújo-Vilar, MD, Professor of Medicine, Division of Endocrinology and Nutrition, University Clinical Hospital of Santiago de Compostela (Spain). “A common feature of most lipodystrophies is the predisposition to diabetes mellitus, dyslipidemia and cardiovascular diseases. Through increased awareness and education, physicians can more accurately diagnose and effectively treat these serious diseases.”

“Our objectives for World Lipodystrophy Day include raising awareness of the public health problem posed by lipodystrophy, implementing actions that impact the challenges faced by patients with lipodystrophy and their families, and joining together with the community to pool resources and improve care for those affected by this rare disease,” said Naca Pérez de Tudela, president of AELIP.

To learn more about lipodystrophy, visit www.aelip.orgwww.lipodystrophyunited.org or http://www.lipodystrophy.co.uk.  

About Aegerion Pharmaceuticals

Aegerion Pharmaceuticals is a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating, rare diseases. For more information about the company, please visit www.aegerion.com.

         CONTACT:
         Aegerion Pharmaceuticals, Inc.
         Amanda Murphy
         Associate Director, Investor & Public Relations
         857-242-5024

Om Nasdaq GlobeNewswire

Nasdaq GlobeNewswire
Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

+1 212 401 8700http://www.nasdaqomx.com

NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.

Følg saker fra Nasdaq GlobeNewswire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Nasdaq GlobeNewswire

Tier1CRM Receives Significant Equity Capital to Accelerate Growth11.12.2017 23:28Pressemelding

Raises $34 Million (USD) from Leading Financial and Strategic Investors to Continue Building on Recent Successes TORONTO and NEW YORK, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Tier1CRM (Tier1), a provider of cloud-based customer relationship management (CRM) solutions for the capital markets industry, announced today that it raised $34 million (USD) in growth equity financing from a group of investors led by Wavecrest Growth Partners, with participation from MassMutual Ventures and Salesforce Ventures. Founded in 2008 by Mark Notten and Phil Dias and based in Toronto, Tier1 is a leading provider of CRM and customer engagement SaaS solutions to sell-side and buy-side financial services clients spanning sales and trading desks, investment banks and investment managers. Major global financial institutions leverage the Tier1 platform to efficiently and more profitably manage client relationships, improve internal transparency and collaboration, manag

Minerva Neurosciences Names Richard Russell President11.12.2017 22:40Pressemelding

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the appointment of Rick Russell as President.  Dr. Remy Luthringer will continue as Chief Executive Officer of Minerva while resigning his position as President. Mr. Russell has more than 20 years of experience leading commercial operations, including developing and implementing sales and marketing activities for major biotechnology and pharmaceutical brands in North America and the European Union.  His experience encompasses several therapeutic areas, including CNS disorders, neurodegenerative disorders, cardiovascular disease and women's health. "We welcome Rick Russell to Minerva, where his wide-ranging commercial expertise will help ensure the effective transition from late-stage clinical development to the market for our product c

Sonoco-Alcore to Increase Paperboard Prices in Europe11.12.2017 22:30Pressemelding

BRUSSELS, Belgium, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sonoco-Alcore S.a.r.l. today announced it will again raise prices by a further €50 per tonne on all recycled paperboard grades sold in the Company's Central European regions. The price change is effective with shipments on or after the 1st January 2018. "The continued strong demand for core board across Europe, along with expectations that already elevated raw material and energy prices will continue to rise into the New Year, leave us little choice but to implement this increase," said Phil Woolley, Director - Paper Europe. Sonoco-Alcore S.a.r.l. is wholly-owned by Sonoco (NYSE:SON) and operates 29 tubes and cores plants and four paperboard mills in Europe. Contact: Roger Schrum +843/339-6018 roger.schrum@sonoco.com     This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corpor

Minerva Neurosciences Elects William Doyle and Hans Peter Hasler to Board of Directors11.12.2017 14:15Pressemelding

WALTHAM, Mass., Dec. 11, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced the election of William F. Doyle and Hans Peter Hasler to the Board of Directors of the Company. "Bill Doyle and Hans Peter Hasler bring distinguished leadership backgrounds and complementary sets of expertise to Minerva's Board of Directors," said Dr. Fouzia Laghrissi-Thode, Board member and chairperson of the search committee at Minerva.  "Their bio-pharma industry-specific experience, which encompasses strategic development, partnering, licensing, product launches, marketing and commercialization, will benefit Minerva as the foundation is laid for the commercialization of the Company's products currently in advanced clinical development.  We look forward to Bill's and Hans's entrepreneurial and operational perspectives on how Minerva can b

Sabina Gold & Silver Announces Commencement of the Review of its Water License Applications for the Back River Project11.12.2017 13:30Pressemelding

VANCOUVER, British Columbia, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Sabina Gold & Silver Corp (TSX:SBB.T), ("Sabina" or the "Company") is pleased to announce that the Nunavut Water Board (NWB) has commenced public review of the Type A and Type B water license applications related to initial development, mine construction and operation of the Back River Project (the "Project" or "Back River"). As announced on December 6, 2017, the Minister of Indigenous and Northern Affairs Canada, on behalf of the five responsible federal Ministers, accepted Nunavut Impact Review Board's recommendation for the Project to proceed to the regulatory and licensing phase.  The NIRB has advised that the final Project Certificate will be issued on or before January 4, 2018. The Type B water license would enable Sabina to commence certain initial pre-development activities in 2018 including onsite construction of service roads and laydown pads, and the mobilization of fuel, supplies and equipment at t

Standard Lithium Provides Development Update on California Lithium Project11.12.2017 11:00Pressemelding

VANCOUVER, British Columbia, Dec. 11, 2017 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (FRA:S5L) (OTCQX:STLHF) is pleased to provide an update on the development work taking place at the Company's California Lithium Project; comprising the Bristol Dry Lake and the Cadiz Dry Lake lithium brine properties located in the Mojave Desert, California. A total of six new separate evaporation ponds have been installed on the Bristol Dry Lake Property to further assess the role that short-duration passive solar evaporation may play in processing the lithium brines encountered at the project.  Previous work demonstrated that, owing to extremely high evaporation rates in the project area, it is possible to concentrate brines from initial lithium concentrations of 146 mg/L to concentrations of 686 mg/L in approximately 7 weeks (note, this average lithium concentration was previously reported as 556 mg/L in news release dated 10th Oct 2017,

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom